Member Info for Krone

Loving it!!!

“Although oncology remains the primary focus of this asset, this bulwarks our intellectual property position and gives us optionality to explore opportunities in other therapeutic areas."

Https://twitter.com/angelosgeo/status/1672311322514432003?s=46&t=_cUs6qcowyQbbF4MoPYSCw

On the basis that SRA737 is Phase 3 ready, albeit part-owned, Sareum's pipeline is further advanced!!!

Dice Therapeutics pipeline at broadly similar stage to Sareum!

https://endpts.com/lilly-inks-2-4b-cash-deal-to-buy-dice-and-its-immunology-pipeline/

https://www.dicetherapeutics.com/pipeline/

Spot the difference “which is getting underway”….”which is progressing to plan and at pace”….

Wondering if the Head of IR is actually in the loop?

Https://www.evaluate.com/vantage/articles/insights/other-data/unpartnered-assets-shelf-or-hidden-treasure

Ahfam - wholly ineffective/inadequate IR/PR may have something to do with it!

Wondering if Sareum will hot up a little this month…..

Https://twitter.com/icr_london/status/1666115854080126982?s=46&t=_cUs6qcowyQbbF4MoPYSCw

Hi BB, absolutely agree, brilliant news and a fantastic achievement!! The apparent absence of market interest is somewhat baffling. PR/IR has often been disappointing however we may see a change following the appointment of Lauren Williams, an IR/PR specialist. There will be plenty of near term opportunities to really bang the Sareum drum!

Good afternoon RMM and thank you once again for your munterings.

It seems to me that there as been a very long standing deficiency in respect of the quality/frequency/timing of news/information/market stimulation which has come into much sharper focus recently. I am holding my breath somewhat however the recent engagement of Lauren Williams as the new Head of IR may be the catalyst that brings about really positive change. Lauren is an independent IR specialist i.e. not employed by either of the brokers, with a very impressive CV/track record and the credibility that goes with it. It is long overdue however we should reasonably expect to see some seriously dynamic IR/PR in coming days and weeks. Let's see how the first dosing and 737 news is handled.

Sorry to hear about your bee sting and yes, enjoy the sun while it lasts!

ATVB

Good afternoon RMM, I am sure many on here would be interested to hear your current Sareum thoughts….I certainly would!

Many thanks and ATB

Https://meetings.asco.org/abstracts-presentations/

High profile venue for announcement re SRA737?

C79 - certainly appears that the field is becoming increasingly crowded!

I’d expect Stephen to be riding shotgun at the conference to cover off the business side of things.

Only days or a couple of weeks at most until:

Confirmation of first dosing with lead compound - clearly the Australians are working at pace to get the 1801 trial up and running.

Confirmation of next steps for SRA737 - potentially significant upfront payment of which Sareum will receive 27.5%

Step change in IR/PR/news flow following the appointment of highly credible independent IR specialist,

Further HNWI involvement,

June conference in Boston,

+++

The board remain sharply focussed on enhancing shareholder value…….it has been a hell of a long haul but we have never been closer!!

Https://twitter.com/kennethbaillie/status/1658856466617384960?s=46&t=_cUs6qcowyQbbF4MoPYSCw

….In the example of TYK2, there is now a therapeutic test of the genetic predictions. Our previous report of association between higher expression and critical illness1 led directly to the inclusion of a new drug, baricitinib, in a large clinical trial; the result demonstrated a clear therapeutic benefit3. This therapeutic signal is consistent across multiple trials, providing the first proof-of-concept for drug target identification using genetics in critical illness and infectious disease.

https://www.nature.com/articles/s41586-023-06034-3

Https://endpts.com/sobi-to-acquire-cti-biopharma-and-its-approved-jak-inhibitor-for-1-7b/

Potnak, thanks. So who are the cheerleaders?